A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.

A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.

CD47 is an immune checkpoint protein that downregulates both the innate and adaptive anti-tumor immune response via its counter receptor SIRPα. Biologics, including humanized CD47 monoclonal antibodies and decoy SIRPα receptors, that block the SIRPα-CD47 interaction, are currently being developed as...

Full description

Bibliographic Details
Main Authors: Teresa L Burgess, Joshua D Amason, Jeffrey S Rubin, Damien Y Duveau, Laurence Lamy, David D Roberts, Catherine L Farrell, James Inglese, Craig J Thomas, Thomas W Miller
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0226661

Internet

https://doi.org/10.1371/journal.pone.0226661

Similar Items